Insulin-like growth factor 1 2026-11-05
Insulin-like growth factor 1 is a peptide hormone and growth mediator associated with growth hormone action. The liver supplies an important circulating source, and IGF-1 signalling helps coordinate growth of tissues including cartilage and bone. The regulatory pathway therefore connects a pituitary signal with growth-related responses in other tissues.[ref]
Anatomy and Physiology 2e by J. Gordon Betts and others. Section 17.3: Growth Hormone and Figure 17.10, liver-derived insulin-like growth factors and tissue growth
The motivating experiment was to look for a measurable activity in blood serum. A 1957 report by W. D. Salmon Jr. and William Daughaday examined a hormonally controlled serum factor through sulfate incorporation by cartilage in vitro.[ref]
A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro by W. D. Salmon Jr. and William Daughaday. Publication title and bibliographic record
In his later account, William Daughaday described cartilage culture and sulfate uptake as the readout that motivated the hypothesis of a serum mediator of growth hormone action.[ref]Growth hormone axis overview: somatomedin hypothesis by William Daughaday. Author retrospective, abstract: cartilage assay and the serum-mediator hypothesis
This was a functional assay: it detected what a serum preparation did to a tissue. Identifying the responsible molecules required further biochemical work. In 1978, E. Rinderknecht and R. E. Humbel reported structural homology between serum-derived IGF-I and proinsulin, providing a molecular basis for the insulin-like designation.[ref]
The historical progression connects three kinds of evidence: pituitary control, a tissue response to blood serum, and molecular identification of a protein. A serum bioactivity measurement and a measurement of one purified hormone answer different experimental questions.
William Daughaday 2026-11-05
William H. Daughaday was a researcher in endocrinology whose work helped connect growth hormone to circulating growth-promoting factors, including insulin-like growth factor 1. He became the founding chief of Washington University's Metabolism Division in 1951 and later led its diabetes and endocrine research centers. The division's institutional history also credits his work on corticosteroid-binding globulin and early measurements of growth hormone and prolactin.[ref]
William H. Daughaday, MD by Washington University in St. Louis. institutional history, division leadership and scientific contributions
With W. D. Salmon Jr., Daughaday investigated why blood serum could stimulate sulfate incorporation in isolated cartilage. The resulting somatomedin hypothesis made an important conceptual separation: a hormone released by one organ can act through another circulating signal. Daughaday's 2000 retrospective describes the historical experiments behind that interpretation; later identification of insulin-like growth factor 1 gave a molecular identity to an important part of this activity.[ref]
Growth hormone axis overview: somatomedin hypothesis by William Daughaday. historical account of the serum-factor experiments
The distinction remains useful when interpreting experiments: observing a growth hormone-dependent response in a whole animal does not show that growth hormone acts directly on the responding tissue.